comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 16:17:13 - browse：5982

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Lupron, used to halt puberty in children, may cause lasting health problems

WSS

DeSantis can now import cheaper drugs. But will Biden get credit?

Heart disease and mental health: A look at cardiac psychology

Drug cartel violence flares in western Mexico after vigilante leader's killing

The SUPPORT Act is critical to fighting the opioid crisis

Undocumented workers face uncertainty as immigration law takes effect in Florida

Generative AI mines health records to identify patients’ social needs

hotspot

comprehensive

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Guidelines to prevent youth baseball injuries need more muscle

New England Journal of Medicine addresses racist history, slavery

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Affirmative action in medical school literally saved lives

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Moonlake's readout produced a cash windfall. Risks remain

Canadians with cystic fibrosis outlive Americans by a decade

leisure time

A letter from the executive editor: The 2023 STATUS List

DeSantis can now import cheaper drugs. But will Biden get credit?

Security flaws in third

Risky weight loss products often used by teens globally, per study

Dexcom's push to bring CGM to type 2 diabetes patients

JPM 2024: Verve Therapeutics looks to mainstream genome editing

focus

explore

explore

explore